Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study

Jiangtao Lai, Bifeng Wu, Tianming Xuan, Zhong Liu, Junzhu Chen, Jiangtao Lai, Bifeng Wu, Tianming Xuan, Zhong Liu, Junzhu Chen

Abstract

Background: Patients with mixed hyperlipidemia usually are in need of combination therapy to achieve low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) target values for reduction of cardiovascular risk. This study investigated the efficacy and safety of adding a new hypolipidemic agent, coenzyme A (CoA) to stable statin therapy in patients with mixed hyperlipidemia.

Methods: In this multi-center, 8-week, double-blind study, adults who had received ≥8 weeks of stable statin therapy and had hypertriglyceridemia (TG level at 2.3-6.5 mmol/L) were randomized to receive CoA 400 U/d or placebo plus stable dosage of statin. Efficacy was assessed by the changes in the levels and patterns of lipoproteins. Tolerability was assessed by the incidence and severity of adverse events (AEs).

Results: A total of 304 patients with mixed hyperlipidemia were randomized to receive CoA 400 U/d plus statin or placebo plus statin (n = 152, each group). After treatment for 8 weeks, the mean percent change in TG was significantly greater with CoA plus statin compared with placebo plus statin (-25.9% vs -4.9%, respectively; p = 0.0003). CoA plus statin was associated with significant reductions in TC (-9.1% vs -3.1%; p = 0.0033), LDL-C (-9.9% vs 0.1%; p = 0.003), and non- high-density lipoprotein cholesterol (-13.5% vs -5.7%; p = 0.0039). There was no significant difference in the frequency of AEs between groups. No serious AEs were considered treatment related.

Conclusions: In these adult patients with persistent hypertriglyceridemia, CoA plus statin therapy improved TG and other lipoprotein parameters to a greater extent than statin alone and has no obviously adverse effect.

Trial registration: Current Controlled Trials ClinicalTrials.gov ID NCT01928342.

Figures

Figure 1
Figure 1
Patient disposition throughout the study.
Figure 2
Figure 2
Mean percent change in triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and non-HDL-C from baseline to the end of treatment. CoA = coenzyme A. *P < 0.01.
Figure 3
Figure 3
The role of coenzyme A in tricarboxylic acid cycle (citric acid cycle).

References

    1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809. doi: 10.1038/362801a0.
    1. Li JJ, Fang CH. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses. 2004;63:100–102. doi: 10.1016/j.mehy.2004.01.029.
    1. Martin SS, Blumenthal RS, Miller M. LDL cholesterol: the lower the better. Med Clin North Am. 2012;96:13–26. doi: 10.1016/j.mcna.2012.01.009.
    1. Szapary PO, Rader DJ. The triglyceride-high-density lipoprotein axis: an important target of therapy? Am Heart J. 2004;148:211–221. doi: 10.1016/j.ahj.2004.03.037.
    1. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. Residual Risk Reduction Initiative (R3I) The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5:319–335. doi: 10.3132/dvdr.2008.046.
    1. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–1361. doi: 10.1093/eurheartj/ehr112.
    1. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med. 2010;362:1563–1574.
    1. Farnier M. Safety review of combination drugs for hyperlipidemia. Expert Opin Drug Saf. 2011;10:363–371. doi: 10.1517/14740338.2011.540237.
    1. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997;80:608–613. doi: 10.1016/S0002-9149(97)00430-X.
    1. McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs. 2011;71:1917–1946. doi: 10.2165/11208090-000000000-00000.
    1. Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, Hou R, Qin Y. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol. 2012;110:1296–1301. doi: 10.1016/j.amjcard.2012.06.050.
    1. Goldberg AC. Combination therapy of dyslipidemia. Curr Treat Options Cardiovasc Med. 2007;9:249–258. doi: 10.1007/s11936-007-0020-7.
    1. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronay disease. N Engl J Med. 2001;345:1583–1592. doi: 10.1056/NEJMoa011090.
    1. Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, Toth PD, Favrot LK, Kerzner B, Nash SD, Bays HE, Simmons PD. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89:672–678. doi: 10.1016/S0002-9149(01)02338-4.
    1. Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008;102:1040–1045. doi: 10.1016/j.amjcard.2008.05.056.
    1. Maki KC, Lubin BC, Reeves MS, Dicklin MR, Harris WS. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. J Clin Lipidol. 2009;3:33–38. doi: 10.1016/j.jacl.2008.12.007.
    1. Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E. Effects of prescription omega-3-acid ethyl esters on non–high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc. 2010;85:122–128. doi: 10.4065/mcp.2009.0397.
    1. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354–1367. doi: 10.1016/j.clinthera.2007.07.018.
    1. Sullivan DR, Sanders TA, Trayner IM, Thompson GR. Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil. Atherosclerosis. 1986;61:129–134. doi: 10.1016/0021-9150(86)90072-9.
    1. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy. 2007;27:715–728. doi: 10.1592/phco.27.5.715.
    1. Lippi G, Favaloro EJ. Antisense therapy in the treatment of hypercholesterolemia. Eur J Intern Med. 2011;22:541–546. doi: 10.1016/j.ejim.2011.06.015.
    1. Daugherty M, Polanuyer B, Farrell M, Scholle M, Lykidis A, de Crécy-Lagard V, Osterman A. Complete reconstitution of the human coenzyme A biosynthetic pathway via comparative genomics. J Biol Chem. 2002;277:21431–21439. doi: 10.1074/jbc.M201708200.
    1. Consolo F, Di Tommaso G, Arrigo F, Trifirò A. Coenzyme A and dyslipidemia. Note III. Action of coenzyme A on changes in the blood lipid pattern after administration of dietary lipids. Boll Soc Ital Biol Sper. 1975;51:1931–1936.
    1. Consolo F, Di Tommaso G, Arrigo F, Trifirò A. Coenzyme A and dyslipidemia. Note I. Rapid changes in lipid and lipoprotein levels induced with coenzyme A in humans. Boll Soc Ital Biol Sper. 1975;51:1920–1926.
    1. Na D, Jing-Wei P, Da Z, Hai-Yan Z, Qun-Fang Y, Hong C. The effects of an oral preparation of Coenzyme A on serum lipids of food-induced hyperlipidemia in rabbits and rats. Academic Journal of Second Military Medical University. 2004;25:255–257.
    1. Na D, Jing-Wei P, Da Z, Hai-Yan Z, Qun-Fang Y, Hong C. Comparison of an oral preparation of Coenzyme A and pantethinein treatment of food-induced hyperlipidemia in rabbits. Academic Journal of Second Military Medical University. 2005;26:919–921.
    1. Zhao S, Chen Y, Chen J, Lai J. Effect and safety of coenzyme A on Hyperlipidemia. Chinese Journal of New Drugs and Clinical Remedies. 2012;5:242–245.
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III) final report. Circulation. 2002;106:3143–3421.
    1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486.
    1. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601–1610. doi: 10.1016/S0195-668X(03)00347-6.
    1. Kasai T, Miyauchi K, Yanagisawa N, Kajimoto K, Kubota N, Ogita M, Tsuboi S, Amano A, Daida H. Mortality risk of triglyceride levels in patients with coronary artery disease. Heart. 2013;99:22–29. doi: 10.1136/heartjnl-2012-302689.
    1. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–2333. doi: 10.1161/CIR.0b013e3182160726.
    1. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556–563. doi: 10.1016/j.amjcard.2005.04.019.
    1. Alagona P Jr. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care. 2009;15:S65–S73.
    1. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225–1228. doi: 10.1016/j.jacc.2005.07.006.
    1. McCarty MF. Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine. Med Hypotheses. 2001;56:314–317. doi: 10.1054/mehy.2000.1155.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere